trial,pubID,pseudogroup,weeks,group,IgD-/IgM-/IgA-/IgG+/KO-/Antigen++ B cells
G002,G002-611,2.0,8,4,1266.0
G002,G002-710,2.0,8,4,691.0
G002,G002-831,1.0,8,2,121.0
G002,G002-387,2.0,8,4,687.0
G002,G002-136,1.0,8,2,791.0
G002,G002-365,2.0,8,4,500.0
G002,G002-145,1.0,8,2,511.0
G002,G002-396,2.0,8,4,1100.0
G002,G002-630,1.0,8,2,223.0
G002,G002-794,2.0,8,4,375.0
G002,G002-855,1.0,8,2,121.0
G002,G002-104,2.0,8,4,279.0
G002,G002-947,1.0,8,2,82.0
G002,G002-820,1.0,8,2,225.0
G002,G002-293,1.0,8,2,378.0
G002,G002-119,1.0,8,2,156.0
G002,G002-943,1.0,8,2,102.0
G002,G002-230,1.0,8,2,1112.0
G002,G002-957,1.0,8,2,123.0
G002,G002-577,1.0,8,2,261.0
G002,G002-480,1.0,8,2,25.0
G002,G002-341,1.0,8,2,102.0
G002,G002-493,1.0,8,2,18.0
G002,G002-620,1.0,8,2,14.0
